Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
CGTN: How China opens its door wider with island-wide special customs operations in Hainan FTP
-
Sezzle’s MoneyIQ Reaches One Million Lessons in Its First Year
-
Notification of major shareholding
-
Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform
-
Microbix Reports Results for Q4 and Fiscal 2025
-
McFarlane Commences Exploration Drilling at Juby Gold Project
-
Toobit Expands Futures Suite with 200x Leverage for ETHUSDT Perpetual Contracts
-
Appili Therapeutics Announces Closing of First Tranche of Non-Brokered Private Placement
-
Cartier Reports Significant Gold Resource Growth At Cadillac With 9,953,000 tonnes at a grade of 2.40g/t Au for 767,800 Ounces Measured and Indicated, a 7% Increase and 35,185,000 tonnes at a grade of
-
StorageVault to Acquire Six Assets for $71.8 Million, Exceeding $200 Million Completed and Announced Transactions for 2025
-
Knight Therapeutics Announces Health Canada Approval for WYNZORA® to Treat Psoriasis Vulgaris
-
North American Niobium and Critical Minerals Corp. Expands Land Package In Québec
-
Domestic Metals 2025 Year End Update Grants Stock Options
-
Repligen Corporation to Present at J.P. Morgan 2026 Healthcare Conference
-
K Wave Media Issues Corporate Update Highlighting SEC Clearance, Strategic Acquisition, and Financial Restructuring Progress
-
DMG Blockchain Solutions Reports Fourth Quarter and Full Year 2025 Audited Results
-
ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer’s Disease
-
Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion
-
FuelCell Energy Ends FY2025 with Revenue Growth and a Focus on Data Center Opportunities
-
“Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature Medicine
-
Enable Injections Announces Regulatory Approval in Saudi Arabia for the EMPAVELI® Injector based on enFuse® Technology
-
Terra Innovatum Global Honored with Sustainability Special Mention at 2025 UNCA Awards
-
Issue of Supplementary Prospectus
-
Schouw & Co.’s financial calendar 2026
-
Kane Biotech Announces Closing of Private Placement Offering with an Insider of the Company
-
CTO Realty Growth Announces Acquisition of Pompano Citi Centre for $65.2 Million
-
Regenx Receives Funding Support to Advance Proprietary Technology
-
Inno Holdings Inc. Announces 1-for-24 Reverse Stock Split as Part of Strategic Nasdaq Compliance Initiative
-
Man Group PLC : Form 8.3 - Dowlais Group plc
-
Man Group PLC : Form 8.3 - American Axle & Manufacturing Holdings, Inc
-
Yacht Club de Monaco closes the 2025 season with the YCM Awards
-
Schouw & Co. to initiate share buy-back programme of up to DKK 240 million
-
Man Group PLC : Form 8.3 - Unite Group plc
-
CAMP4 Announces Pricing of $30.0 Million Underwritten Offering of Common Stock
-
Dimensional Fund Advisors Ltd. : Form 8.3 - JUST GROUP PLC - Ordinary Shares
-
Dimensional Fund Advisors Ltd. : Form 8.3 - INTERNATIONAL PERSONAL FINAN - Ordinary Shares
-
NRx Pharmaceuticals (Nasdaq:NRXP) announces elimination of all balance sheet debt following equity conversion
-
Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million
-
Anfield Energy Announces Agreement to Acquire BRS Engineering, Bolstering In-House Technical Expertise for Uranium and Vanadium Projects
-
Apollo Silver Secures 100% Interest in Athena Claims at Langtry
-
Celebrate the season island-style: King’s Hawaiian hosts holiday happy hour pop-up in Toronto
-
Aya Gold & Silver Files Preliminary Economic Assessment Technical Report for Boumadine Project
-
Avadel Pharmaceuticals Announces Completion of Enrollment in Phase 3 REVITALYZ™ Trial in Idiopathic Hypersomnia
-
Kamada Announces a $10-$14 Million Extension of Canadian Supply Tender
-
Atavistik Bio Raises $120 Million Series B Financing to Advance the Development of Selective Allosteric Small Molecule Therapeutics for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT) and
-
BioStem Technologies Products Placed on “12-Month Status Quo Period” List in Update to CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes
-
Mutuum Finance (MUTM) Strengthens Security Framework with CertiK Review and Active Halborn Audit
-
Hydreight Exceeds 1.3 Million Product Orders Placed, Surpassing 2025 Operational Targets
-
Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination
-
Talisker Provides Update on Staff Reduction at Bralorne due to Atmospheric River Event in Southern British Columbia
